Effect of Vitamin D on stress-induced hyperglycaemia and insulin resistance in critically ill patients

International Journal of Clinical Practice

Volumn 70, Issue 5, 2016, Pages 396-405

  Alizadeh, N ^a   Khalili, H ^a   Mohammadi, M ^b   Abdollahi, A ^b   Ala, S ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ADIPONECTIN; COLECALCIFEROL; GLUCOSE; INSULIN; PLACEBO; 25-HYDROXYVITAMIN D; GLUCOSE BLOOD LEVEL; VITAMIN; VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STRESS; STRESS INDUCED HYPERGLYCEMIA; SURGICAL PATIENT; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; CRITICAL ILLNESS; METABOLISM; MIDDLE AGED; PHYSIOLOGICAL STRESS; POSTOPERATIVE COMPLICATIONS;

ADIPONECTIN; ADULT; AGED; BLOOD GLUCOSE; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; STRESS, PHYSIOLOGICAL; VITAMIN D; VITAMINS;

EID: 84963945601     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12795     Document Type: Article

References (82)

1. Capes SE, Hunt D, Malmberg K, Gerstein HC,. Stress hyperglycemia and Increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-8.
2. Dungan K, Braithwaite SS, Preiser JC,. Stress hyperglycemia. Lancet 2009; 373: 1798-807.
3. Badawi O, Waite MD, Fuhrman SA, Zuckerman IH,. Association between intensive care unit-acquired dysglycemia and in-hospital mortality. Crit Care Med 2012; 40: 3180-8.
4. Bruno A, Levine SR, Frankel MR, et al., Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002; 59: 669-74.
5. American Diabetes Association. Diabetes Statistics. Diabetes Basics, 2010. http://www.diabetes.org (accessed April 2015).
6. Moghissi ES, Korytkowski MT, DiNardo M, et al., American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 2009; 15 (4): 353-69.
7. van den Berghe G, Wouters P, Weekers F, et al., Intensive insulin therapy incritically ill patients. N Engl J Med 2001; 345: 1359-67.
8. Umpierrez GE, Isaacs SD, Bazargan N, et al., Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87 (3): 978-82.
9. Krinsley JS,. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78 (12): 1471-8.
10. Farrokhi F, Smiley D, Umpierrez GE,. Glycemic control in non-diabetic critically ill patients. Best Pract Res Clin Endocrinol Metab 2011; 25 (5): 813-24.
11. Taylor JH, Beilman GJ,. Hyperglycemia in the intensive care unit: no longer just a marker of illness severity. Surg Infect (Larchmt) 2005; 6 (2): 233-45.
12. Xiu F, Stanojcic M, Diao L, Jeschke MG,. Stress hyperglycemia, insulin treatment, and innate immune cells. Int J Endocrinol 2014; 2014: 486403.
13. Marik PE, Raghavan M,. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004; 30 (5): 748-56.
14. Mizock BA,. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001; 15: 533-51.
15. Mehta VK, Hao W, Brooks-Worrell BM, Palmer JP,. Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol 1994; 130: 208-14.
16. Krenitsky J,. Glucose control in the intensive care unit: a nutrition support perspective. Nutr Clin Pract 2011; 26 (1): 31-43.
17. Brunkhorst FM, Engel C, Bloos F, et al., Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39.
18. Preiser JC, Devos P, Ruiz-Santana S, et al., A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucose Control study. Intensive Care Med 2009; 35: 1738-48.
19. Kajbaf F, Mojtahedzadeh M, Abdollahi M,. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Therapy 2007; 4 (1): 97-106.
20. Mezza T, Muscogiuri G, Sorice GP, et al., Vitamin D deficiency: a new risk factor for type 2 diabetes? Ann Nutr Metab 2012; 61: 337-48.
21. Maestro B, Campión J, Dávila N, Calle C,. Stimulation by 1,25-dihydroxyvitamin D 3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47: 383-91.
22. Zemel MB,. Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Mol Cell Biochem 1998; 188: 129-36.
23. Reusch JE, Begum N, Sussman KE, Draznin B,. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. J Endocrinol 1991; 129: 3269-73.
24. Borissova A, Tankova T, Kirilov G, Dakovska L, Kovacheva R,. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003; 57 (4): 258-61.
25. Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T,. Effect of 1α(OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner 1986; 1 (3): 187-92.
26. Nagpal J, Pande JN, Bhartia A,. A double blind, randomized, placebo-controlled trial of the short-term effect of vitamin D 3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009; 26: 19-27.
27. Von Hurst PR, Stonehouse W, Coad J,. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br J Nutr 2010; 103: 549-55.
28. Mitri J, Muraru MD, Pittas AG,. Vitamin D and type 2 diabetes: a systematic review (review). Eur J Clin Nutr 2011; 65: 1005-15.
29. Orwoll E, Riddle M, Prince M,. Effects of vitamin D on insulin and glucagon secretion in non-insulin- dependent diabetesmellitus. Am J Clin Nutr 1994; 59 (5): 1083-7.
30. George PS, Pearson ER, Witham MD,. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med 2012; 29: e-142.
31. Ljunghall S, Lind L, Lithell H, et al., Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance. A prospective randomized double-blind study. Acta Med Scand 1987; 4: 361-7.
32. DIAsource 25OH Vitamin D Total ELISA Kit instruction. Louvain-la Neuve, Belgium. KAP1971 http://www.diasource-diagnostics.com (accessed June 2014).
33. Insulin Elisa Kit instruction of DiaMetra, Italy. http://www.diametra.com (accessed June 2014).
34. Borai A, Livingstone C, Kaddam I, Ferns G,. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol 2011; 11: 158.
35. Human Adiponectin (ADP) Elisa Kit instruction of Shanghai, Crystal Day Biotech Company, China. Http://www.bt-labratory.com (accessed June 2014).
36. Lau CH, Muniandy S,. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovasc Diabetol 2011; 10: 8.
37. McCowen KC, Malhotra A, Bistrian BR,. Stress-induced hyperglycemia. Crit Care Clin 2001; 17 (1): 107-24.
38. Baker ST, Chiang CY, Zajac JD, Bach LA, Jerums G, MacIsaac RJ,. Outcomes for general medical inpatients with diabetes mellitus and new hyperglycaemia. Med J 2008; 188 (6): 340-3.
39. Krinsley JS,. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78: 1471-8.
40. Ganai S, Lee KF, Merrill A, et al., Adverse outcomes of geriatric patients undergoing abdominal surgery who are at high risk fo delirium. Arch Surg 2007; 148: 1072-8.
41. Frisch A, Chandra P, Smiley D, et al., Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care 2010; 33: 1783-8.
42. Liu E, Meigs JB, Pittas AG, et al., Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139 (2): 329-34.
43. Rudnicki PM, Mølsted-Pedersen L,. Effect of 1,25-dihydroxycholecalciferol on glucose metabolism in gestational diabetes mellitus. Diabetologia 1997; 40: 40-4.
44. Autier P, Boniol M, Pizot C, Mullie P,. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014; 2 (1): 76-89.
45. Tellioglu A, Basarana S, Guzela R,. Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly. Maturitas 2012; 72: 332-8.
46. Pearce SH, Cheetham TD,. Diagnosis and management of vitamin D deficiency. BMG 2010; 340: 142-7.
47. Diamond TH, Ho KW, Rohl PG, Meerkin M,. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust 2005; 183 (1): 10-2.
48. Lee P,. How deficient are vitamin D deficient critically ill patients?. Crit Care 2011; 15 (2): 154.
49. Wu F, Staykova T, Horne A, et al., Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. N Z Med J 2003; 116 (1179): U536.
50. Ilahi M, Armas LA, Heaney RP,. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008; 87 (3): 688-91.
51. Amrein K, Schnedl C, Berghold A, Pieber TR, Dobnig H,. Correction of vitamin D deficiency in critically ill patients-VITdAL@ICU study protocol of a double-blind, placebo-controlled randomized clinical trial. BMC Endocr Disord 2012; 12: 27.
52. Mazahery H, von Hurst PR,. Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation. Nutrients 2015; 7 (7): 5111-42.
53. Zittermann A, Ernst JB, Gummert JF, Borgermann J,. Vitamin D supplementation, body weight and human serum 25-hydroxyvitamin D response: a systematic review. Eur J Nutr 2014; 53: 367-74.
54. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ,. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77 (1): 204-10.
55. Waterhouse M, Tran B, Armstrong BK, et al., Environmental, personal, and genetic determinants of response to vitamin D supplementation in older adults. J Clin Endocrinol Metab 2014; 99 (7): E1332-40.
56. Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW,. 25-hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008; 87 (6): 1738-42.
57. Romagnoli E, Mascia ML, Cipriani C, et al., Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 2008; 93 (8): 3015-20.
58. Zabihiyeganeh M, Jahed A, Nojomi M,. Treatment of hypovitaminosis d with pharmacologic doses of cholecalciferol, oral vs intramuscular; an open labeled rct. Clin Endocrinol 2013; 78: 210-6.
59. Mata-Granados JM, Vargas-Vasserot J, Ferreiro-Vera C, Luque De Castro MD, Pavon RG, Quesada Gomez JM,. Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method. J Steroid Biochem Mol Biol 2010; 2: 452-5.
60. Borai A, Livingstone C, Ferns G,. The biochemical assessment of insulin resistance. Ann Clin Biochem 2007; 44: 324-42.
61. Pittas AG, Lau J, Hu FB, Dawson-Hughes B,. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92 (6): 2017-29.
62. Maestro B, Campion J, Davila N, Calle C,. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47 (4): 383-91.
63. Williams PF, Caterson ID, Cooney GJ, Zilkens RR, Turtle JR,. High affinity insulin binding and insulin receptor-effector coupling: modulation by Ca2 +. Cell Calcium 1990; 11 (8): 547-56.
64. Van Etten E, Mathieu C,. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. Steroid Biochem Mol Biol 2005; 97 (1-2): 93-101.
65. Taylor A, Wise PH,. Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgr Med J 1998; 74 (872): 365-6.
66. Iraj B, Aminorroaya A, Amini M,. Does the intramuscular injection of vitamin D increase insulin resistance? J Res in Pharm Pract 2012; 1 (2): 60-5.
67. Sugden J, Davies J, Witham MD, Struthers AD,. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008; 25: 320-32.
68. Spedding S, Vanlint S, Morris S, Scragg R,. Does vitamin D sufficiency equate to a single serum 25-hydroxyvitamin D level or are different levels required for non-skeletal diseases? Nutrients 2013; 5: 5127-39.
69. Ouchi N, Kihara S, Funahashi T, et al., Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107 (5): 671-4.
70. Dyck DJ,. Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab 2009; 34 (3): 396-402.
71. Yu YH, Ginsberg HN,. Adipocyte signaling and lipid homeostasis:sequelae of insulin-resistant adipose tissue. Circ Res 2005; 96 (10): 1042-52.
72. Matsuzawa Y,. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005; 6 (2): 7-14.
73. Gannagé-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G,. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol 2009; 160: 965-71.
74. Nimitphong H, Chanprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B,. The association between vitamin D status and circulating adiponectin independent of adiposity in subjects with abnormal glucose tolerance. Endocrine 2009; 36: 205-10.
75. Vaidya A, Forman JP, Underwood PC, et al., The influence of body-mass index and renin-angiotensin-aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men. Eur J Endocrinol 2011; 164: 995-1002.
76. Breslavsky A, Frand J, Matas Z, Boaz M, Barnea Z, Shargorodsky M,. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients. Clin Nutr 2013; 32 (6): 970-5.
77. Kern PA, Di Gregorio GB, Lu T, et al., Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-85.
78. Arita Y, Kihara S, Ouchi N, et al., Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257 (1): 79-83.
79. Wajchenberg BL,. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
80. Koch A, Sanson E, Voigt S, Helm A, Trautwein C, Tacke F,. Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients. J Crit Care 2011; 26 (2): 166-74.
81. Matsuhisa M, Yamasaki Y, Emoto M, et al., A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract 2007; 77: 151-4.
82. Zaletel J, Barlovic DP, Prezelj J,. Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with Type 2 diabetes. J Endocrinol Invest 2010; 33: 514-8.